These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters. Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993 [TBL] [Abstract][Full Text] [Related]
28. On the biological activity of anti-ICAM-1 oligonucleotides complexed to non-viral carriers. Lucas B; Van Rompaey E; Remaut K; Sanders N; De Smedt SC; Demeester J J Control Release; 2004 Apr; 96(1):207-19. PubMed ID: 15063042 [TBL] [Abstract][Full Text] [Related]
29. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles. Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711 [TBL] [Abstract][Full Text] [Related]
30. Treatment of multidrug-resistant murine leukemia with antisense mdr1 oligodeoxynucleotides. Hiratake S; Azuma E; Nishiguchi Y; Nagai M; Ido M; Komada Y; Sakurai M Biomed Pharmacother; 1997; 51(6-7):276-83. PubMed ID: 9309248 [TBL] [Abstract][Full Text] [Related]
31. Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides. Thierry AR; Rahman A; Dritschilo A Biochem Biophys Res Commun; 1993 Feb; 190(3):952-60. PubMed ID: 8094959 [TBL] [Abstract][Full Text] [Related]
33. In vitro cytotoxic activity of cationic paclitaxel nanoparticles on MDR-3T3 cells. Niu G; Castro CH; Nguyen N; Sullivan SM; Hughes JA J Drug Target; 2010 Jul; 18(6):468-76. PubMed ID: 20059301 [TBL] [Abstract][Full Text] [Related]
34. Folic acid-polylysine carrier improves efficacy of c-myc antisense oligodeoxynucleotides on human melanoma (M14) cells. Ginobbi P; Geiser TA; Ombres D; Citro G Anticancer Res; 1997; 17(1A):29-35. PubMed ID: 9066627 [TBL] [Abstract][Full Text] [Related]
35. Use of cyclodextrin and its derivatives as carriers for oligonucleotide delivery. Zhao Q; Temsamani J; Agrawal S Antisense Res Dev; 1995; 5(3):185-92. PubMed ID: 8785474 [TBL] [Abstract][Full Text] [Related]
36. Effect of Pluronic on cellular uptake of cationic liposomes- mediated antisense oligonucleotides. Chen HL; Hu QH; Liang WQ Pharmazie; 2004 Feb; 59(2):131-3. PubMed ID: 15025182 [TBL] [Abstract][Full Text] [Related]
37. Cationic nanoemulsion as a delivery system for oligonucleotides targeting malarial topoisomerase II. Bruxel F; Cojean S; Bochot A; Teixeira H; Bories C; Loiseau PM; Fattal E Int J Pharm; 2011 Sep; 416(2):402-9. PubMed ID: 21291974 [TBL] [Abstract][Full Text] [Related]
38. Selection of antisense oligonucleotides for reversal of multidrug resistance in breast carcinoma cells. Gao P; Zhou GY; Lei DP; Zhang XF; Li L; Xu JW; Lin XY Cytotherapy; 2007; 9(8):795-801. PubMed ID: 17917879 [TBL] [Abstract][Full Text] [Related]
39. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression. Dean N; McKay R; Miraglia L; Howard R; Cooper S; Giddings J; Nicklin P; Meister L; Ziel R; Geiger T; Muller M; Fabbro D Cancer Res; 1996 Aug; 56(15):3499-507. PubMed ID: 8758918 [TBL] [Abstract][Full Text] [Related]